1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
636CC1E9F2FB7E8160025855400485CC0
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/functionality-technology-platforms-during-global-covid-19-pandemic
18
19
2018.97.14.85
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Business Operations » Information Technology

Evolution of Technology Platforms during the Global COVID-19 Pandemic and Beyond

ID: CM-4


Features:

9 Info Graphics

20 Data Graphics

490+ Metrics

25 Narratives


Pages: 40


Published: 2020


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
With the COVID-19 pandemic impacting key business operations across the world, organizations have had to adapt or stand up new technologies and communication platforms to continue their support to patients and interact with physicians, thought leaders and other internal and external stakeholders.

Video Brief


As part of our "Managing through COVID-19 and Beyond" benchmark research series, Best Practices LLC conducted this study to track the rapid evolution in virtual infrastructure and digital engagement platforms within life sciences companies as a result of the global COVID-19 pandemic.

This new report examines critical new system functionalities by assessing a wide range of digital communication and collaboration platforms, the frequency usage and effectiveness of various modes of technology, and evolving strategies and approaches for enhancing engagement through innovative operating models in the post-COVID-19 world.


Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Medical Device; Laboratories; Biopharmaceutical; Manufacturing; Consumer Products; Consulting; Science; Marketing; Clinical Research


Companies Profiled:
Abbott; ADC Therapeutics; Advanced Accelerator Applications; Align Technology; Alkem; Alkermes; Allergan; Almirall; Alnylam Pharmaceuticals; AstraZeneca; Bayer; Boehringer Ingelheim; B. Braun; Chiesi; Daiichi Sankyo; Deciphera Pharmaceuticals; DiaSorin; Eisai; EMD Serono; GE Healthcare; Grünenthal; Ipsen; IDEXX Laboratories; Kyowa Kirin; Lundbeck; Merck; Nabriva Therapeutics; Novartis; Proteus Digital Health; Sandoz; Sanofi Genzyme; Santen; Takeda Pharmaceuticals; The Stem; Thermo Fisher Scientific; UCB Pharma; Vifor Pharma; Wellspect HealthCare; West 53rd St Digital; Worldwide Clinical Trials

Study Snapshot

Best Practices, LLC engaged 54 leaders at 40 life sciences organizations in this research. Nearly 70% of the participants are at the director/ head level.

Key topics covered in this report include:

  • Technology implementation achievements and challenges
  • Usage of digital communicative and collaborative platforms
  • Technology used to support internal and external stakeholder communication
  • Internal and external communication approach post-COVID-19
  • Technology change duration


Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Multifunctional support of technology platforms: Respondents regularly favor digital platforms that provide file sharing, collaboration and communication tools on a single platform. Almost 60% of Microsoft Teams users have increased their use of the platform since the pandemic, while 50% plan to make continue with how they already used Skype for Business. Zoom was the second most adopted platform behind MS Teams.
  • Physician-focused online engagement still lags: Mandatory virtual outreach has necessitated streamlined discussion methods. Unfortunately, e-detailing and e-sampling lack effectiveness at this point.

Table of Contents

Sr. No.
Topic
Slide No.
I.
Overviewpgs. 3-5
Universe of Learningpg. 4
Key Actionspg. 5
II.
Operational Achievements and Challengespgs. 6-9
III.
Digital Communicative and Collaborative Platformspgs. 10-14
IV.
External Stakeholder Communicationpgs. 15-22
V.
Internal Stakeholder Communicationpgs. 23-27
VI.
Technology Change Durationpgs. 28-30
VII.
Participant Demographicspgs. 31-32
VIII.
Appendixpgs. 33-39
IX.
About Best Practices, LLCpg. 40

    List of Charts & Exhibits

    I. Operational Achievements and Challenges

    • Improvement in efficiency of work flow operations due to technology implementation in light of current events
    • Struggles and/or hindrances experienced or expected to experience by benchmark participants around the use of technology during the global pandemic

    II. Digital Communicative and Collaborative Platforms

    • Digital communicative and collaborative platforms currently being implemented by benchmark organizations to add tactical functionality due to the emergence of the global pandemic
    • Changes in company’s operations in implementing technology platforms because of the COVID-19 crisis – Newly adopted digital communicative and collaborative platforms
    • Changes in company’s operations in implementing technology platforms because of the COVID-19 crisis – Increased usage of digital communicative and collaborative platforms
    • Changes in company’s operations in implementing technology platforms because of the COVID-19 crisis – Continued use as always of digital communicative and collaborative platforms

    III. External Stakeholder Communication

    • Frequency and effectiveness of various modes of technology used to support external stakeholder communication
    • External stakeholder communication before COVID-19, current implications and opportunities
    • Use of any new technologies for external communication in the next 12 weeks
    • Maximizing virtual ad boards
    • Expected changes in streamlined virtual technology functionalities and platforms for external operations post COVID-19 pandemic

    IV. Internal Stakeholder Communication

    • Frequency and effectiveness of various modes of technology used to support internal stakeholder communication
    • Use of any new technologies for internal communication in the next 12 weeks
    • Expected changes in streamlined virtual technology functionalities and platforms for internal operations post COVID-19 pandemic

    V. Technology Change Duration

    • Technology change duration
    • Approach towards dealing with technology changes after the global pandemic is over for external stakeholder operations
    • Approach towards dealing with technology changes after the global pandemic is over for internal stakeholder operations